Cognoptix is a leading brand in the field of non-invasive Alzheimer's diagnostics. With a strong focus on providing innovative and effective solutions, Cognoptix is developing a simple and non-invasive eye scanning test for the early detection and diagnosis of Alzheimer's disease. This test, which can be conveniently conducted in a doctor's office, empowers both physicians and patients to proactively manage their cognitive health.

The key to effective treatment of Alzheimer's lies in early detection, and Cognoptix aims to be the pioneer in offering an early warning system for the disease. By combining a laser eye scanning device with a specialized eye ointment that binds to beta amyloid, a crucial protein associated with Alzheimer's, Cognoptix has successfully demonstrated early clinical results. The accumulation of amyloid deposits in the brain can also be detected and measured in the lens of the eye.

With its commitment to providing accurate, safe, and cost-effective diagnostic solutions, Cognoptix is addressing the significant unmet need for a reliable and accessible test for Alzheimer's disease. Co-founded by Dr. Lee Goldstein and Dr.

Leo Chylack from Brigham and Women's Hospital in Boston, Cognoptix is at the forefront of revolutionizing Alzheimer's diagnostics and bringing about a positive impact on patients' lives